BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, February 28, 2026
See today's BioWorld
Home
» Negative development: Why VCs say no to deals varies, but with verities
To read the full story,
subscribe
or
sign in
.
Negative development: Why VCs say no to deals varies, but with verities
Oct. 29, 2015
By
Randy Osborne
Science or technology that fails to measure up and weak leadership make for sure-fire deal-killers in the venture capital (VC) world, but there's more to it, said Jay Lichter, managing partner with Avalon Ventures in San Diego.
BioWorld